SymbolMNKD
NameMANNKIND CORP
SectorHEALTH CARE
RegionNorth America
IndustryPharmaceutical Preparations
Address1 CASPER STREET, DANBURY, CT 06810
Telephone818-661-5000
Fax
Email
Websitehttps://www.mannkindcorp.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0000899460
Description

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Additional info from NASDAQ:
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

2026-08-14 17:08

New Form SCHEDULE 13G - MANNKIND CORP <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001104659-26-097084 <b>Size:</b> 14 KB

Read more
2026-08-11 00:44

Binder Steven B. 🔴 sold 39.1K shares of MANNKIND CORP (MNKD) at $4.06 Transaction Date: Aug 07, 2026 | Filing ID: 343016

Read more
2026-08-07 20:39

📋 STEVEN BINDER (Director) plans to sell 39K shares of MannKind Corporation (at $3.89 each, total $152K) Filed: Aug 07, 2026 | ID: 007817

Read more
2026-08-05 20:01

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

Read more
2026-07-31 11:47

New Form SCHEDULE 13G - MANNKIND CORP <b>Filed:</b> 2026-07-31 <b>AccNo:</b> 0002100119-26-001503 <b>Size:</b> 7 KB

Read more
2026-07-29 10:30

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

Read more
2026-07-24 10:35

MannKind Announces $50 Million Private Placement

Read more
2026-07-24 10:30

MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

Read more
2026-07-18 01:47

Prentiss Christopher B 🔴 sold 22.2K shares of MANNKIND CORP (MNKD) at $4.09 Transaction Date: Jul 15, 2026 | Filing ID: 308139

Read more
2026-07-18 01:47

Marasco Dominic 🔴 sold 3.6K shares of MANNKIND CORP (MNKD) at $4.09 Transaction Date: Jul 15, 2026 | Filing ID: 308137

Read more